LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Hyperferritinemia associated with systemic manifestations of Mycoplasma pneumoniae infection.

    Borsboom, Daniel / Matthys, Imke / Van Steenkiste, Christophe

    Acta clinica Belgica

    2019  Volume 75, Issue 4, Page(s) 312

    MeSH term(s) Humans ; Hyperferritinemia ; Pneumonia, Mycoplasma
    Language English
    Publishing date 2019-03-28
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 390201-8
    ISSN 2295-3337 ; 0001-5512 ; 1784-3286
    ISSN (online) 2295-3337
    ISSN 0001-5512 ; 1784-3286
    DOI 10.1080/17843286.2019.1599569
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.283: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Positive and Negative Affect Changes during Gender-Affirming Hormonal Treatment: Results from the European Network for the Investigation of Gender Incongruence (ENIGI).

    Matthys, Imke / Defreyne, Justine / Elaut, Els / Fisher, Alessandra Daphne / Kreukels, Baudewijntje P C / Staphorsius, Annemieke / Den Heijer, Martin / T'Sjoen, Guy

    Journal of clinical medicine

    2021  Volume 10, Issue 2

    Abstract: Improving transgender people's quality of life (QoL) is the most important goal of gender-affirming care. Prospective changes in affect can influence QoL. We aim to assess the impact of initiating gender-affirming hormonal treatment (HT) on affect. In ... ...

    Abstract Improving transgender people's quality of life (QoL) is the most important goal of gender-affirming care. Prospective changes in affect can influence QoL. We aim to assess the impact of initiating gender-affirming hormonal treatment (HT) on affect. In the European Network for the Investigation of Gender Incongruence (ENIGI) study, we prospectively collected data of 873 participants (451 transwomen (TW) and 422 transmen (TM)). At baseline, psychological questionnaires including the Positive and Negative Affect Schedule (PANAS) were administered. The PANAS, levels of sex steroids and physical changes were registered at each follow-up visit during a 3-year follow-up period, starting at the initiation of hormonal therapy. Data were analyzed cross-sectionally and prospectively. Over the first three months, we observed a decline in positive affect (PA) in both TM and TW. Thereafter, PA reached a steady state in TW, whereas in TM there was also a second decline at 18 months. In both TM and TW there was no persisting difference comparing baseline to the 36-months results. Concerning negative affect (NA), we observed a decline during the first year in TM, which sustained during the second year and was not different anymore at 36 months compared to baseline. In TW though, we did not find any change of NA during the entire follow-up. Even if some of these results show significant differences, they should be considered with caution, since there was no control group and the absolute differences are small. No association between affect and the level of sex steroids was observed. Baseline QoL and psychological burden are related to affect independently from gender but are not necessarily good predictors of the evolution of one's affect during the gender-affirming process. Further research is necessary to investigate these preliminary results.
    Language English
    Publishing date 2021-01-14
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm10020296
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Positive and Negative Affect Changes during Gender-Affirming Hormonal Treatment

    Imke Matthys / Justine Defreyne / Els Elaut / Alessandra Daphne Fisher / Baudewijntje P. C. Kreukels / Annemieke Staphorsius / Martin Den Heijer / Guy T’Sjoen

    Journal of Clinical Medicine, Vol 10, Iss 2, p

    Results from the European Network for the Investigation of Gender Incongruence (ENIGI)

    2021  Volume 296

    Abstract: Improving transgender people’s quality of life (QoL) is the most important goal of gender-affirming care. Prospective changes in affect can influence QoL. We aim to assess the impact of initiating gender-affirming hormonal treatment (HT) on affect. In ... ...

    Abstract Improving transgender people’s quality of life (QoL) is the most important goal of gender-affirming care. Prospective changes in affect can influence QoL. We aim to assess the impact of initiating gender-affirming hormonal treatment (HT) on affect. In the European Network for the Investigation of Gender Incongruence (ENIGI) study, we prospectively collected data of 873 participants (451 transwomen (TW) and 422 transmen (TM)). At baseline, psychological questionnaires including the Positive and Negative Affect Schedule (PANAS) were administered. The PANAS, levels of sex steroids and physical changes were registered at each follow-up visit during a 3-year follow-up period, starting at the initiation of hormonal therapy. Data were analyzed cross-sectionally and prospectively. Over the first three months, we observed a decline in positive affect (PA) in both TM and TW. Thereafter, PA reached a steady state in TW, whereas in TM there was also a second decline at 18 months. In both TM and TW there was no persisting difference comparing baseline to the 36-months results. Concerning negative affect (NA), we observed a decline during the first year in TM, which sustained during the second year and was not different anymore at 36 months compared to baseline. In TW though, we did not find any change of NA during the entire follow-up. Even if some of these results show significant differences, they should be considered with caution, since there was no control group and the absolute differences are small. No association between affect and the level of sex steroids was observed. Baseline QoL and psychological burden are related to affect independently from gender but are not necessarily good predictors of the evolution of one’s affect during the gender-affirming process. Further research is necessary to investigate these preliminary results.
    Keywords affect ; quality of life ; gender-affirming hormonal treatment ; PANAS questionnaire ; estrogens ; testosterone ; Medicine ; R
    Subject code 150
    Language English
    Publishing date 2021-01-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: A plethora of manifestations following a

    Matthys, Imke / Borsboom, Daniel / Steyaert, Sophia / Vervloet, Delphine / Cornelis, Kristoff / Vanderstraeten, Erik / Kindt, Sébastien / Dewint, Pieter / Lambrecht, Valerie / Sinnaeve, Peter / Van Steenkiste, Christophe

    Acta clinica Belgica

    2019  Volume 75, Issue 3, Page(s) 229–234

    Abstract: Mycoplasma ... ...

    Abstract Mycoplasma pneumoniae
    MeSH term(s) Abdominal Pain ; Acute Coronary Syndrome/etiology ; Acute Coronary Syndrome/physiopathology ; Adult ; Anti-Bacterial Agents/therapeutic use ; Azithromycin/therapeutic use ; Cholestasis/etiology ; Cholestasis/physiopathology ; Coronary Aneurysm/etiology ; Coronary Aneurysm/physiopathology ; Cough/etiology ; Cough/physiopathology ; Diarrhea/drug therapy ; Diarrhea/etiology ; Diarrhea/physiopathology ; Fever ; Glucocorticoids/therapeutic use ; Hepatitis/drug therapy ; Hepatitis/etiology ; Hepatitis/physiopathology ; Humans ; Ileitis/drug therapy ; Ileitis/etiology ; Ileitis/physiopathology ; Male ; Mycoplasma Infections/complications ; Mycoplasma Infections/drug therapy ; Mycoplasma Infections/physiopathology ; Mycoplasma pneumoniae ; Pneumonia, Mycoplasma/complications ; Pneumonia, Mycoplasma/drug therapy ; Pneumonia, Mycoplasma/physiopathology ; Recurrence ; Uveitis, Anterior/drug therapy ; Uveitis, Anterior/etiology ; Uveitis, Anterior/physiopathology ; Vasculitis/drug therapy ; Vasculitis/etiology ; Vasculitis/physiopathology
    Chemical Substances Anti-Bacterial Agents ; Glucocorticoids ; Azithromycin (83905-01-5)
    Language English
    Publishing date 2019-02-15
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 390201-8
    ISSN 2295-3337 ; 0001-5512 ; 1784-3286
    ISSN (online) 2295-3337
    ISSN 0001-5512 ; 1784-3286
    DOI 10.1080/17843286.2019.1578029
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.283: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top